Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON52433
NL-OMON52433
Recruiting
N/A

The effect of different radiotherapy regimen on the immune cell landscape - The effect of radiotherapy on immune cell landscape

Radboud Universitair Medisch Centrum0 sites200 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscancertumor10027656

Overview

Phase
N/A
Intervention
Not specified
Conditions
cancer
Sponsor
Radboud Universitair Medisch Centrum
Enrollment
200
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- treated with radiotherapy for cancer at the Radboudumc
  • •\- understand dutch
  • •\- mentally competent
  • •\- 30\-80 years old

Exclusion Criteria

  • •\- autoimmune disease
  • •\- immune\- suppressive drugs (with the exception of \<\= 10 mg prednisone or
  • •equivalent doses of corticosteroids).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Investigation on radiotherapy treatment effect using perfusion and diffusion-weighted MR imagingtumor
JPRN-UMIN000014439Kyoto Univerisity Hospital
Active, Not Recruiting
Phase 1
Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. - Codeleted
EUCTR2008-007295-14-ATEORTC488
Active, Not Recruiting
N/A
Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. - Codeleted
EUCTR2008-007295-14-GBEORTC488
Active, Not Recruiting
Phase 1
Phase III intergroup Study of Radiotherapy versus TemozolomideAlone versus Radiotherapy with concomitant and adjuvantTemozolomide for Patients with 1p/19q Codeleted AnaplasticGlioma.ewly Diagnosed Anaplastic Glioma with Chromosomal co-deletions of 1p and 19qMedDRA version: 19.0Level: PTClassification code 10002224Term: Anaplastic astrocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10027744Term: Mixed astrocytoma-oligodendrogliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10026659Term: Malignant oligodendrogliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2008-007295-14-NLEuropean Organization for Research and Treatment of Cancer (EORTC)488
Completed
Phase 3
Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.anaplastic oligodendroglial tumors10029211
NL-OMON44004European Organisation for Research in Treatment of Cancer (EORTC)54